Terkko Navigator / Hemminki, A(kseli)*

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.

Familial Risks and Mortality in Second Primary Cancers in Melanoma.

Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms?

Second primary cancers in non-Hodgkin lymphoma: family history and survival.

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients.

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Effect of genetic modifications on physical and functional titers of adenoviral cancer gene therapy constructs.

Familial Associations of Colon and Rectal Cancers With Other Cancers.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Second primary cancer after female breast cancer: Familial risks and cause of death.

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction.

Multiple myeloma: family history and mortality in second primary cancers.

Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

Familial associations of male breast cancer with other cancers.

Familial associations of female breast cancer with other cancers.

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.

Familial Associations of Colorectal Cancer with Other Cancers.

Other cancers in lung cancer families are overwhelmingly smoking-related cancers.

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Genetics of gallbladder cancer.

Cancer-targeted oncolytic adenoviruses for modulation of the immune system.

TILT Biotherapeutics.

Power and limits of modern cancer diagnostics: cancer of unknown primary.

Risk of other Cancers in Families with Melanoma: Novel Familial Links.

Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models.

Concordant and discordant familial cancer: Familial risks, proportions and population impact.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Common cancers share familial susceptibility: implications for cancer genetics and counselling.

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.

The epidemiology of metastases in neuroendocrine tumors.

Familial Associations Between Prostate Cancer and Other Cancers.

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.

Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer.

Metastatic spread in patients with gastric cancer.

Patterns of metastasis in colon and rectal cancer.

Adenoviral delivery of tumor necrosis factor alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma.

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

A century of oncolysis evolves into oncolytic immunotherapy.

Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy.

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.